CompletedPhase 2psilocybin
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Sponsored by COMPASS Pathways
NCT ID
NCT03775200
Target Enrollment
233 participants
Start Date
2019-03-01
Est. Completion
2021-09-27
About This Study
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
Conditions Studied
Interventions
- •Psilocybin
Eligibility
Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Diagnosis of TRD Exclusion Criteria: * Other comorbidities
Study Locations (25)
Kadima Neuropsychiatry Institute
La Jolla, California, United States
Altman Clinical and Translational Research Institute, University of California
San Diego, California, United States
Stanford Department of Psychiatry
Stanford, California, United States
Mood and Anxiety Disorders Program Emory University School of Medicine
Atlanta, Georgia, United States
Ray Worthy Psychiatry LLC
New Orleans, Louisiana, United States
Sheppard Pratt Health System
Baltimore, Maryland, United States
New York State Psychiatric Institute
New York, New York, United States
UT Center of Excellence on Mood Disorders, University of Texas Health Science Center
Houston, Texas, United States
Canadian Rapid Treatment Centre of Excellence
Mississauga, Ontario, Canada
Centre for Addiction and Mental Health
Toronto, Ontario, Canada
+15 more locations